electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function...
Neurology
Psyence Group Announces Cantheon Capital Private Placement
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology...
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain...
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
Pharmanovia to acquire license to GHRYVELIN™from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediatelyTORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE)...
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau),...
Healthy Directions Partners with Dr. Kulreet Chaudhary to Combine the Tradition Of Ayurvedic Practice with Modern-Day Science
Dr. Kulreet Chaudhary Partners with Healthy Directions Neurologist and Ayurvedic practitioner, Dr. Kulreet Chaudhary has developed Prajna Ayurveda herbals with...
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology...
electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second LanguageROCKAWAY, N.J., March 13,...
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
Assure Announces Reverse Stock Split
DENVER, March 03, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease...
Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Assure Holdings to Present at the Gravitas 6th Annual Growth Conference
DENVER, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or...
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick...
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years...
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.),...